Where does Regenxbio Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Regenxbio Inc. ranks #33,037 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Regenxbio Inc. hold?

Regenxbio Inc. holds 8 US utility patents granted between 2017 and 2025, spanning 9 technology areas.

What is Regenxbio Inc.'s Innovation Score?

Regenxbio Inc. has an Innovation Score of 50.0 out of 100 (top 14% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Regenxbio Inc.'s patent grant rate increasing or decreasing?

Regenxbio Inc.'s recent grant velocity is +400% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Regenxbio Inc.'s patents?

Regenxbio Inc.'s patents average 19.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Regenxbio Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Regenxbio Inc.

Q: What technology areas does Regenxbio Inc. focus on?

Regenxbio Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 8 patents. Grants appear in 9 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 9 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Regenxbio ranks #33,037 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 9 technology areas.

#33,037
of 49,997 US assignees by volume: Top 14%
by Innovation Score (50.0/100): 19.6
avg claims per patent: +400%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R33037 · US Corporation #33,037 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #33,037/49,997
PHOTO-FINISH Redexim Handel-en…
CPC-NARROW C12N · 9 areas
INNOV-PAR 50.0/100
CLAIMS-RICH 19.6 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +400% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Redexim Handel-en Exploitatie Maatschappit B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Regenxbio · this assignee

50
3D Lighting… · lowest

7

What this shows Regenxbio's Innovation Score is 50.0/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Regenxbio's grants concentrate

Regenxbio Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2017. By volume, Regenxbio sits between Redexim Handel-en Exploitatie Maatschappit B.V. and Remacro Machinery & Technology (WUJIANG) Co., Ltd..

Regenxbio's three-year grant acceleration

Regenxbio Inc. shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Redexim Handel-en…

8
Redknee

8
Reflektion

8
Regenics AS

8
Regwez

8
Reinhold Industri…

8
Reis Group Holdin…

8
Remacro Machinery…

8
Regenxbio ◀

8

What this shows Regenxbio holds 8 patents at rank #32,998, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Regenxbio

By rank, the assignees closest to #32,998 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Regenxbio's primary technology class.

Regenxbio's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Regenxbio Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	12.5%
2023	1	12.5%
2024	4	50.0%
2025partial year	2	25.0%

Which technologies does Regenxbio Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C12Y - Enzymes 5

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

B01D - Separation 2

C07K - Peptides 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 1

Top 9 of 9 technology areas

Where it ranks

Overall rank by patents

#33,037

of 49,997 tracked assignees

Innovation Score

50.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Regenxbio Inc.'s patent record in context - here's where to go next.

Regenxbio Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #33,037 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Regenxbio Inc. against Redexim Handel-en Exploitatie Maatschappit B.V., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.